Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mallinckrodt Plc (MNK)

Mallinckrodt Plc (MNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 569,935
  • Shares Outstanding, K 83,814
  • Annual Sales, $ 3,216 M
  • Annual Income, $ -3,607,000 K
  • 60-Month Beta 2.33
  • Price/Sales 0.18
  • Price/Cash Flow 0.38
  • Price/Book 0.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.11
  • Number of Estimates 10
  • High Estimate 2.21
  • Low Estimate 2.04
  • Prior Year 1.78
  • Growth Rate Est. (year over year) +18.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.07 +15.41%
on 07/22/19
9.52 -26.42%
on 07/01/19
-1.96 (-21.90%)
since 06/21/19
3-Month
6.07 +15.41%
on 07/22/19
18.77 -62.68%
on 04/25/19
-11.35 (-61.85%)
since 04/23/19
52-Week
6.07 +15.41%
on 07/22/19
36.65 -80.89%
on 08/20/18
-14.93 (-68.07%)
since 07/23/18

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK

Pomerantz LLP is investigating claims on behalf of investors of Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

MNK : 7.07 (+3.97%)
Watch for Mallinckrodt to Potentially Rebound After Falling 3.03% Yesterday

Mallinckrodt (NYSE:MNK) traded in a range yesterday that spanned from a low of $6.12 to a high of $7.13. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $6.75 on...

MNK : 7.07 (+3.97%)
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA1 interference (RNAi) therapeutics...

MNK : 7.07 (+3.97%)
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES

SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES

MNK : 7.07 (+3.97%)
SLNCF : 1.9000 (+9.20%)
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA2 interference (RNAi) therapeutics...

MNK : 7.07 (+3.97%)
SLNCF : 1.9000 (+9.20%)
After Yesterday's Decline of 7.20%, Mallinckrodt Offers Investors Better Value

Mallinckrodt (NYSE:MNK) traded in a range yesterday that spanned from a low of $7.29 to a high of $8.29. Yesterday, the shares fell 7.2%, which took the trading range below the 3-day low of $8.10 on...

MNK : 7.07 (+3.97%)
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of...

MNK : 7.07 (+3.97%)
Shares of MNK Down 54.9% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mallinckrodt (NYSE:MNK) on April 18th, 2019 at $18.65. In approximately 3 months, Mallinckrodt has returned 54.86% as of today's recent price of $8.42.

MNK : 7.07 (+3.97%)
Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MNK : 7.07 (+3.97%)
Shares of Medicines Comp Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (MDCO , MNK , NKTR , MYL , LCI )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

MDCO : 36.17 (-0.71%)
MNK : 7.07 (+3.97%)
NKTR : 32.06 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade MNK with:

Business Summary

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media...

See More

Key Turning Points

2nd Resistance Point 7.39
1st Resistance Point 7.10
Last Price 7.07
1st Support Level 6.29
2nd Support Level 5.77

See More

52-Week High 36.65
Fibonacci 61.8% 24.97
Fibonacci 50% 21.36
Fibonacci 38.2% 17.75
Last Price 7.07
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar